U.S. Markets open in 5 hrs 42 mins

Nektar Therapeutics (NKTR)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
21.500+0.40 (+1.90%)
At close: 4:00PM EDT
People also watch
NBIXALKSMDCOPGNXSGEN
Interactive chart
Previous Close21.100
Open21.150
Bid15.190 x 100
Ask22.800 x 100
Day's Range20.570 - 21.550
52 Week Range11.410 - 24.880
Volume1,673,322
Avg. Volume2,219,639
Market Cap3.34B
Beta2.30
PE Ratio (TTM)-15.65
EPS (TTM)-1.37
Earnings DateAug 1, 2017 - Aug 7, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.88
Trade prices are not sourced from all markets
  • PR Newswire4 days ago

    New Research Collaboration between Nektar and Takeda to Explore Combination Cancer Therapy Approaches with NKTR-214, a CD122-Biased Agonist, and Five Takeda Cancer Therapy Compounds

    SAN FRANCISCO, May 22, 2017 /PRNewswire/ -- Nektar Therapeutics (NKTR) announced today that Takeda Pharmaceutical Company Limited (TSE: 4502) and Nektar have entered into a research collaboration to explore the combination of Nektar's lead immuno-oncology candidate, the CD122-biased agonist NKTR-214, with five oncology compounds from Takeda's cancer portfolio.  The two companies will explore the anti-cancer activity of NKTR-214 with five different targeted mechanisms in preclinical tumor models of lymphoma, melanoma and colorectal cancer. "We look forward to collaborating with Takeda to explore a range of combination therapy approaches in models of both liquid and solid tumors," said Jonathan Zalevsky, PhD, Senior Vice President of Biology and Preclinical Development.

  • Bristol-Incyte Match Beats Dow's Merck In Combination Trials
    Investor's Business Daily6 days ago

    Bristol-Incyte Match Beats Dow's Merck In Combination Trials

    Incyte stock enjoyed a fifth consecutive day of gains Friday after its immuno-oncology drug proved robust in combination trials with Merck and Bristol.

  • Nektar Therapeutics breached its 50 day moving average in a Bearish Manner : NKTR-US : May 18, 2017
    Capital Cube8 days ago

    Nektar Therapeutics breached its 50 day moving average in a Bearish Manner : NKTR-US : May 18, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Nektar Therapeutics. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average ... Read more (Read more...)